Combination of antibiotics — Competitive Intelligence Brief

Combination of antibiotics (Combination of antibiotics) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antibiotic combination. Area: Infectious Disease.

phase 3 Antibiotic combination Infectious Disease Small molecule

Target snapshot

Combination of antibiotics (Combination of antibiotics) — Assistance Publique - Hôpitaux de Paris. A combination of antibiotics that work synergistically to inhibit bacterial cell wall synthesis and protein production, targeting multiple pathways to overcome resistance.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Combination of antibiotics TARGET	Combination of antibiotics	Assistance Publique - Hôpitaux de Paris	phase 3	Antibiotic combination
Helicobacter pylori eradication	Helicobacter pylori eradication	National Cancer Center, Korea	marketed	Antibiotic combination therapy / Proton pump inhibitor-based regimen
Ceftolozane-tazobactam + Meropenem	Ceftolozane-tazobactam + Meropenem	National University of Singapore	marketed	Beta-lactam antibiotic combination	Bacterial penicillin-binding proteins (PBPs); beta-lactamase inhibition
Ciprofloxacin Tablets & Metronidazole tablets	Ciprofloxacin Tablets & Metronidazole tablets	MinaPharm Pharmaceuticals	marketed	Fluoroquinolone + Nitroimidazole antibiotic combination	Bacterial DNA gyrase, topoisomerase IV (ciprofloxacin); anaerobic DNA (metronidazole)
Ceftazidime-avibactam + Aztreonam	Ceftazidime-avibactam + Aztreonam	National University of Singapore	marketed	β-lactam antibiotic combination with β-lactamase inhibitor	Bacterial penicillin-binding proteins; β-lactamases
Polysporin Triple	Polysporin Triple	University Health Network, Toronto	marketed	Topical antibiotic combination	Bacterial cell wall (bacitracin), bacterial ribosome (neomycin), bacterial cell membrane (polymyxin B)
PPI, amoxicillin, metronidazole and clarithromycin	PPI, amoxicillin, metronidazole and clarithromycin	Infante, Javier Molina, M.D.	marketed	Antibiotic combination therapy with acid suppression	Helicobacter pylori (bacterial pathogen); PPI targets H+/K+-ATPase; amoxicillin targets bacterial cell wall; metronidazole and clarithromycin target bacterial protein synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antibiotic combination class)

1. Michael E. DeBakey VA Medical Center · 2 drugs in this class
2. University of South Florida · 2 drugs in this class
3. Halmstad County Hospital · 1 drug in this class
4. Hospital General Universitario Elche · 1 drug in this class
5. Hospital de Clinicas de Porto Alegre · 1 drug in this class
6. McMaster University · 1 drug in this class
7. Assistance Publique - Hôpitaux de Paris · 1 drug in this class
8. Shanghai Jiao Tong University School of Medicine · 1 drug in this class
9. The Cleveland Clinic · 1 drug in this class
10. The Forsyth Institute · 1 drug in this class